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The development of the human cerebral cortex is a complex and dynamic process,
in which neural stem cell proliferation, neuronal migration, and post-migratory neuronal
organization need to occur in a well-organized fashion. Alterations at any of
these crucial stages can result in malformations of cortical development (MCDs),
a group of genetically heterogeneous neurodevelopmental disorders that present with
developmental delay, intellectual disability and epilepsy. Recent progress in genetic
technologies, such as next generation sequencing, most often focusing on all protein-
coding exons (e.g., whole exome sequencing), allowed the discovery of more than a
100 genes associated with various types of MCDs. Although this has considerably
increased the diagnostic yield, most MCD cases remain unexplained. As Whole
Exome Sequencing investigates only a minor part of the human genome (1–2%),
it is likely that patients, in which no disease-causing mutation has been identified,
could harbor mutations in genomic regions beyond the exome. Even though functional
annotation of non-coding regions is still lagging behind that of protein-coding genes,
tremendous progress has been made in the field of gene regulation. One group
of non-coding regulatory regions are enhancers, which can be distantly located
upstream or downstream of genes and which can mediate temporal and tissue-specific
transcriptional control via long-distance interactions with promoter regions. Although
some examples exist in literature that link alterations of enhancers to genetic disorders, a
widespread appreciation of the putative roles of these sequences in MCDs is still lacking.
Here, we summarize the current state of knowledge on cis-regulatory regions and
discuss novel technologies such as massively-parallel reporter assay systems, CRISPR-
Cas9-based screens and computational approaches that help to further elucidate the
emerging role of the non-coding genome in disease. Moreover, we discuss existing
literature on mutations or copy number alterations of regulatory regions involved in brain
development. We foresee that the future implementation of the knowledge obtained
through ongoing gene regulation studies will benefit patients and will provide an
explanation to part of the missing heritability of MCDs and other genetic disorders.
Keywords: malformations of cortical development, gene regulation, cis-regulatory elements, enhancers,
epigenome, functional genomics, massively parallel reporter assays, bioinformatics
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INTRODUCTION
The brain lies at the foundation of what makes us human,
as it not only regulates most of our body functions, but it
is also central to our cognition and thoughts, defining our
personalities, behavior and social interactions. How such a
complex organ is formed during development has fascinated
biologists for centuries, and we are now living in a technology
driven era where knowledge gained through various disciplines
such as medicine, biotechnology, computational biology, and
neuroscience enables us for the first time to get a glimpse on how
these intricate processes are genetically regulated. Understanding
the developmental biology of the human brain is not only of
utmost importance for satisfying our own natural curiosity of
what makes us human, but also promises improvements and
therapeutic options for various disorders that affect the human
brain, including neurodevelopmental and neurodegenerative
diseases, which, together, are a burden on society and have a
negative effect on the quality of life of individuals (Genereaux
et al., 2015; Jonsson et al., 2017). One of the traditionally
best studied parts of the human brain is the cerebral cortex,
which is responsible for cognition and sensorimotor activity. The
development of the cerebral cortex is a complex and dynamic
process organized in three major steps: (I) neural stem cell
proliferation, (II) neuronal migration toward the cortical plate,
and (III) post-migratory organization (for further review see,
Agirman et al., 2017; Van Essen et al., 2018; Seto and Eiraku,
2019). Alterations in any of these steps can be responsible
for the development of a group of disorders overall known as
malformations of cortical development (MCD), a common cause
of neurodevelopmental delay, intellectual disability and epilepsy
(Guerrini and Dobyns, 2014).
Malformations of cortical development are a heterogeneous
group of disorders originally classified into three main groups,
reflecting the stage of cortical development at which the defect
arises (Barkovich et al., 1996). To date, more than a 100
genes associated with MCDs have been described (Guerrini and
Dobyns, 2014), the majority of which encodes for proteins that
function in general neurodevelopmental processes such as cell
cycle regulation, neuronal migration, and polarization. These
include classically studied MCD genes such as LIS1, that, when
mutated, causes lissencephaly (Reiner et al., 1993), but also a
flood of recently identified genes such as TLE1 (Cavallin et al.,
2018), GRIN1 (Fry et al., 2018), CRADD (Di Donato et al., 2016),
DIAPH1 (Ercan-Sencicek et al., 2015), WDR62 (Bilguvar et al.,
2010), RTTN (Kheradmand Kia et al., 2012), ZIC1 (Vandervore
et al., 2018), MACF1 (Dobyns et al., 2018), and many more
(Lu et al., 2018) that could only be implicated in MCD due
to the advent of next-generation DNA sequencing technologies,
which enable large-scale genomic investigations in an unbiased,
hypothesis-free manner.
Potential disease-causing genetic mutations can be detected
by whole exome sequencing (WES), a method of sequencing all
protein-coding exons in a genome. Although the implementation
of WES in the diagnostic process improved the diagnostic yield
of Mendelian disorders to ∼25–30% (Yang et al., 2013), still
many cases of MCDs remain unexplained (de Wit et al., 2008).
This holds true even for cases where multiple affected individuals
are found in the same family, or other environmental causes
have been excluded, strongly hinting at a genetic cause. Even
though the diagnostic yield for some MCD groups displaying
very defined features on brain imaging, such as lissencephaly
(characterized by a smooth brain surface with absent gyri), can
reach up to 80% (Di Donato et al., 2018), for the vast majority
of cases of the remaining MCD spectrum the yield is much
lower (Wiszniewski et al., 2018). Cases displaying this “missing
heritability” are often reasoned to be caused by somatic mutations
(Jamuar et al., 2014; Gonzalez-Moron et al., 2017), mosaicism
(McMahon et al., 2015; Mirzaa et al., 2016; Zillhardt et al., 2016)
or by non-genetic causes, such as viral infections (Bosnjak et al.,
2011; Moore et al., 2017). However, as WES only interrogates
the 1–2% of the human genome that encodes for proteins
(Consortium, 2012), it is tempting to speculate that at least some
of this missing heritability of MCD might be caused or influenced
by genetic variation in the non-coding genome. This hypothesis is
supported by several arguments. First, genome-wide association
(GWAS) studies on multiple diseases have shown that more
than 90% of disease-associated single nucleotide polymorphisms
(SNPs) are located outside of coding genes (Maurano et al.,
2012), therefore potentially in regions involved in transcriptional
regulation. Second, the last decade has witnessed an enormous
progress in our understanding of mechanisms involved in gene
regulation that find their origin in the non-coding genome, and it
has become clear that aberrant gene regulation can cause a variety
of genetic disorders (Zeng et al., 2015; Smith and Flodman, 2018;
Spielmann et al., 2018). Key elements in the non-coding genome
such as promoters, insulators and enhancers, the latter also
referred to as non-coding regulatory elements (NCREs), ensure
that genes are turned on or off at the right moment in time. When
this tight spatio-temporal regulation is disturbed, gene expression
can be affected which could result in a genetic disorder. Although
only very few large-scale genetic studies have investigated the
role of the non-coding genome in genetic disorders (Doan et al.,
2016; Devanna et al., 2018; Short et al., 2018) it is clear from
the number of excellent studies that have recently been published
(Lettice et al., 2002, 2003; Benko et al., 2009; Smemo et al., 2012;
Weedon et al., 2014; Ngcungcu et al., 2017; Protas et al., 2017;
Bouman et al., 2018; Gloss and Dinger, 2018; Mehrjouy et al.,
2018; Potuijt et al., 2018), that it will only be a matter of time until
the community fully realizes the importance of the non-coding
genome in health and disease. Finally, one and the same mutation
can show different degrees of severity in different patients, and
it is likely that this phenotypic variability could be influenced
by genetic variations outside of coding genes influencing gene
expression (Castel et al., 2018; Niemi et al., 2018).
In this Review, we will first provide a concise overview of the
current state-of-the-art of the field of gene regulation and the
role herein of the non-coding genome, with a particular focus
on enhancers. We will review recently developed technology and
computational approaches that will facilitate future investigations
on non-coding causes of MCDs and will discuss examples of
non-coding alterations causing genetic diseases. We conclude
this Review by providing an example of a strategy to identify
regulatory alterations in patients with MCDs. Together, this
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will provide a perspective on how “missing heritability” will
be identified in the near future and how to move beyond the
borders of the exome.
THE NON-CODING GENOME AND ITS
ROLE IN GENE REGULATION
According to the central dogma of molecular biology, there
are three main processes taking place in the cell: replication
of the genetic information, transcription of DNA into RNA,
and translation of the RNA molecule into the final functional
product, the protein (Crick, 1958). As one of the main surprises
from the Human Genome Project, it is now well-established
that more than 98% of the human genome does not encode
proteins (Consortium, 2012). These non-protein-coding regions
were initially considered as junk DNA, which was assumed to be
redundant and under no selective pressure, thus allowing for the
accumulation of mutations without any harm to the organism
(Ohno, 1972; Kuska, 1998). However, several structural elements
of non-coding DNA have now been described that regulate gene
expression, by determining the 3D genomic organization critical
for correct gene regulation. Regulation of gene transcription
is particularly crucial during embryonic development, when a
single cell needs to differentiate into distinct cell types and to
establish diverse gene expression programs in order to acquire a
broad range of phenotypes, while maintaining the same genotype.
This is achieved by a tight spatio-temporal regulation of gene
expression, that allows the transcription of the right gene, at
the right level, in the right cell type, and is executed by the
interplay between enhancers and gene promoters confined to the
“playfield” established by the 3D organization of the genome. It
is important to keep in mind in the following paragraphs, that
gene regulation, unlike coding DNA, needs to be seen from a non-
linear, 3D perspective where regulatory elements need to interact
with target genes on long distances.
Genomic organization comprises efficient DNA packaging
in the limited space of the nucleus while allowing for DNA
replication and gene expression. First, nucleosomes are formed,
in which 147 bp of DNA are wrapped around eight histone
proteins linked to each other by DNA stretches of various
lengths. This beads-on-a-string organization forms the basis of
a 10-nm chromatin fiber that is typical of open chromatin,
also known as euchromatin. This differs from tightly packaged
heterochromatin, where multiple histones wrap into a 30-nm
fiber consisting of nucleosome arrays in their most compact
form. As a result of this, chromatin is organized into active and
inactive compartments that are either open or condensed and
which vary in size between 1 to 10 megabases (Mb). Inactive
compartments are often found in association with the nuclear
lamina, whereas active compartments are more likely to be found
in other regions of the nucleus (van Steensel and Belmont,
2017). Regulatory elements such as enhancers and promoters
and actively transcribed genes are located in open-chromatin
regions, so that they are accessible for the transcriptional
machinery. Various post-translational epigenetic modifications
of histones put in place by chromatin modifying enzymes can
alter the accessibility of chromatin and can thereby influence how
chromatin is packaged and whether it is more or less likely to
be active. For example, histone acetylation results in increased
chromatin accessibility and makes chromatin more available
for the binding of regulatory proteins, such as transcription
factors (TFs). Many studies focused on a wide variety of histone
modifications (see Bannister and Kouzarides, 2011; Hyun et al.,
2017, for Review), and have led to a draft of a histone code, where
various histone modifications are indicative of the functional role
that the chromatin has at those places that are modified. For
example, putative enhancers are enriched in chromatin regions
surrounded by histone 3 lysine 4 monomethylation (H3K4me1)
and lysine 27 acetylation (H3K27ac), while promoters are marked
by histone 3 lysine 4 trimethylation (H3K4me3). Insulators are
responsible for organizing chromatin at a sub-compartment level.
They are often bound by the TF CTCF (also known as 11-zinc
finger protein or CCCTC-binding factor) (Bell et al., 1999) and
establish the boundaries of so-called topologically associating
domains (TADs). TADs are usually <1 Mb in size and delineate
those regions of our chromosomes in which sequences interact
preferentially with each-other rather than with elements in other
regions of the genome. The prevailing model is that these TADs
are formed by the dimerization of two CTCF molecules binding
the boundaries of a TAD and are stabilized by the interaction
with the ring-shaped cohesin complex through a process called
loop extrusion (Dowen et al., 2014; Ong and Corces, 2014; Rowley
and Corces, 2018). Inside TADs, smaller DNA loops are formed
to allow enhancer–promoter interactions and thus regulation
of transcription (Dowen et al., 2014; Hnisz et al., 2016). These
enhancer-promoter loops, similarly to the CTCF-mediated loops,
are thought to be established by the binding and dimerization
of the TF YY1 and its interaction with the cohesin complex
(Figure 1) (Beagan et al., 2017; Weintraub et al., 2017).
Promoters are located around the transcriptional start site
(TSS) of genes and are essential to initiate transcription.
Enhancers are positive regulators of transcription (Banerji et al.,
1981), whose location relative to the TSS of the gene they
control varies from adjacent to the promoter, to many kilobases
(kb) upstream or downstream (e.g., in cis), and can even
be located in introns, also of other genes. Moreover, besides
acting in a position-independent manner, enhancers can regulate
transcription irrespective of their orientation. A classic example
of a long-range regulatory element is the limb SHH enhancer,
which is located ∼1 Mb away from its target gene (Lettice et al.,
2003). Finally, one enhancer can regulate several genes, and at
the same time each gene can be regulated by multiple enhancers.
This creates a redundancy in the system that results in phenotypic
robustness, and probably gives advantages during evolution
(Osterwalder et al., 2018). Therefore, the positions, identities, and
arrangements of cis-regulatory sequences ultimately determine
the time and place that each gene is transcribed. On a
mechanistic level, enhancers directly influence the recruitment of
the transcriptional machinery to the TSS of genes (Stadhouders
et al., 2012; Coulon et al., 2013). Crucial for this long-range
control of gene expression by enhancers is the formation of
enhancer-promoter loops which preferentially occur within the
neighborhood of a TAD, by DNA bending. The general TFs
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FIGURE 1 | Regulatory enhancer-promoter interactions are restricted within the topological associating domain (TAD) region. The genome (here represented as a
black line) is tightly packaged and organized in TADs established by the binding of CTCF to insulator elements, followed by dimerization and interaction with the
cohesin complex. In order to establish the enhancer-promoter loops required for transcriptional regulation, enhancers and their target gene should reside in the same
TAD. These regulatory loops are formed by the dimerization of YY1 and its interaction with cohesin. In the enlargement is a simplified scheme of transcription
initiation (the size does not reflect the actual dimension of each component). Transcription factors (TFs) bind on the enhancer element while the pre-initiation complex
formed by the RNA Pol II and the general TFs assembles at the promoter region. Mediator establishes the connection between enhancer and promoter via
interactions with TF and components of the transcription preinitiation complex, without binding to DNA. Mediator regulates the phosphorylation of the RNA Pol II in
order to release it from the promoter and start transcription.
and the RNA polymerase II bind to the promoter sequence,
whereas the distal cis-regulatory sequences are bound by
TFs, which orchestrate the rate of transcription initiation.
Enhancers include TF binding sites (TFBSs) that typically
consist of DNA motifs found at multiple sites in the genome,
but that are not necessarily all equally likely to be bound
by the recognizing TF (Lambert et al., 2018). To provide
higher than background activity, homotypic or heterotypic
dimerization of transcription regulators increases their DNA
binding affinity and specificity (Funnell and Crossley, 2012).
TF binding itself can also be influenced by DNA methylation,
which is established by DNA methyltransferases (DNMTs) (Yin
et al., 2017). Moreover, if TF binding prevents the DNA from
rewrapping around the nucleosome, it increases the likelihood
that a second transcription regulator binds the DNA, increasing
the cooperative effect to the extent of displacing the histone
core of the nucleosome (Iwafuchi-Doi et al., 2016; Iwafuchi-Doi,
2019). Multiple TFs have been found to bind in a cooperative
manner in TF binding site “hotspots” (Siersbaek et al., 2011), later
called stretch enhancers (Parker et al., 2013) or super-enhancers
(SEs) (Whyte et al., 2013). The latter are described as long regions
with an increased density of enhancer elements characterized
by a strong enrichment of H3K27ac, and of TFs and Mediator
binding (Hnisz et al., 2013; Whyte et al., 2013). On the one
hand, a number of studies suggests that SEs represent a novel
class of NCREs that maintain, define, and control mammalian
cell identity and whose transcriptional regulatory output is larger
than that of the individual enhancer constituents (Young, 2011;
Whyte et al., 2012, 2013; Loven et al., 2013). On the other hand,
an increasing number of studies have challenged this view and
consider super enhancers as a collection of normal enhancers
that together do not have a larger activity than the sum of the
individual parts (Hay et al., 2016; Shin et al., 2016). Therefore,
the debate on whether SE are a new class of NCREs or whether
they simply reflect a clustering of normal NCREs within close
proximity remains to be settled.
What is clear from the above, is that our knowledge on
complex gene regulatory mechanisms has increased dramatically
over the last decade and has provided insights into many
sophisticated processes that need to occur correctly for
development to proceed normally. Aberrations in many of
the steps described above can result in genetic disorders. For
example, in recent years a large number of disorders have been
described that are caused by mutations in chromatin modifying
enzymes or proteins involved in 3D chromatin regulation
(Gregor et al., 2013; Ball et al., 2014; Mirabella et al., 2016;
Holsten et al., 2018). Given the complexity of gene regulation
and the many contributing factors acting at different stages of
this process, it seems likely that many more will be discovered
in the near future.
GENOME-WIDE IDENTIFICATION OF
PUTATIVE ENHANCERS
As introduced in the previous paragraph, transcriptional
enhancers were first described as DNA sequences that are
able to enhance gene expression on an episomal plasmid
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FIGURE 2 | Overview of the main techniques currently used to identify putative enhancer sequences and their interacting genes. (A) Schematic drawing of an
TF-bound enhancer, located in nucleosome depleted DNA from which eRNA is transcribed. Below are representative genome browser tracks shown, illustrating
expected profiles for the same genetic region. Histone-ChIP-seq is illustrative for marks such as H3K27ac and H3K4me1. (B) Cartoon representing the main steps
of the workflow of Chromosome conformation capture technologies: nuclei are cross-linked, chromatin is then digested and re-ligated by proximity ligation. The two
stretches of DNA that are normally located far away from each other (yellow and green), are now ligated together and can be tested by PCR or sequencing. In the
bottom part is indicated the output of the experiment, with which TADs and enhancer-promoter interactions can be identified.
(e.g., a non-integrating, extra chromosomal circular DNA),
irrespective of their location and orientation relative to the
TSS (Banerji et al., 1981; Moreau et al., 1981); thus, enhancer
identification was first limited to low-throughput reporter assays,
where small fragments of DNA were tested for regulatory
activity influencing reporter gene expression. The most widely
applied experimental techniques for genome-wide identification
of putative enhancers at the endogenous genomic locus today
do not rely directly on this functional property, but rather on
features that distinguish enhancers from non-regulatory regions
at the chromatin level. Indeed, enhancers are bound by TFs and
transcription coactivators and are located in open chromatin
regions that are depleted from nucleosomes. The surrounding
nucleosomes have specific histone tail modifications, such as the
previously mentioned H3K4me1 and H3K27ac. Moreover, some
enhancers are bi-directionally transcribed in so-called enhancer
RNAs (eRNAs). However, even though these features correlate
with enhancers, other genomic regions share the same chromatin
characteristics, and more functional tests are required to prove
that putative enhancers are indeed having a direct functional
role in gene regulation (Catarino and Stark, 2018). This led
to the development of high-throughput functional screenings,
overall known as massively parallel reporter assays (MPRAs) that
quantify the enhancer activity of millions of sequences. In the
next paragraphs we will discuss the most widely used techniques
to identify putative regulatory regions (Figure 2 and Table 1),
and in the following section we will focus on high-throughput
functional screens.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was first introduced
more than 30 years ago to study protein-DNA interactions
(Solomon et al., 1988) and it follows three basic steps. First,
proteins are covalently cross-linked to their DNA binding-site by
treating cells with formaldehyde. Chromatin is then sheared, and
protein-DNA complexes are selectively co-immunoprecipitated
with an antibody against the protein of interest. Finally, the
cross-linking is reversed, and DNA is isolated and tested to
identify the binding sites of the protein of interest. In more
recent years, the emergence of next generation sequencing (NGS)
technologies, allowed genome-wide mapping of these protein-
DNA binding sites (ChIP-seq) (Johnson et al., 2007; Robertson
et al., 2007). ChIP-seq is now primarily used to identify putative
enhancers across the entire genome by immunoprecipitation
of TFs, specific histone-tail post-translational modifications,
including H3K4me1 (Heintzman et al., 2007) and H3K27ac
(Creyghton et al., 2010), and transcriptional coactivators, such
as the histone acetyltransferase p300/CBP (Visel et al., 2009) and
Mediator (Whyte et al., 2013). However, neither the binding of a
TF nor the presence of histone modifications provide definitive
evidence that a sequence acts as a transcriptional enhancer. For
example, tissue specific enhancers can have a certain degree of
H3K27ac enrichment in tissues where they are not active (Cotney
et al., 2012) and not all H3K27ac marked DNA sequences show
enhancer activity when functionality tested (Barakat et al., 2018).
Several studies have used ChIP-seq for histone modifications to
predict enhancers during human brain development (Reilly et al.,
2015; Amiri et al., 2018) and in adult brain (Vermunt et al., 2014;
Sun et al., 2016; Li et al., 2018; Wang D. et al., 2018), and some
have made direct comparisons to brains from other primates,
providing important insights in the evolution of humans (Reilly
et al., 2015; Vermunt et al., 2016).
Identification of Open Chromatin
Regions
As abovementioned, cis-regulatory sequences like enhancers
are enriched in chromatin regions depleted from nucleosomes
(Boyle et al., 2008), as nucleosomes would impede TF binding
(Lidor Nili et al., 2010). These accessible DNA regions can be
identified in a genome-wide fashion thanks to several techniques
such as DNase-seq, FAIRE-seq, and ATAC-seq. DNase-seq takes
advantage of the hypersensitivity of open chromatin to nuclease
digestion. Briefly, cell nuclei are isolated, and DNA is digested
with limiting concentrations of DNase I. Fragments of about
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TABLE 1 | Methods for the identification of non-coding regulatory elements (NCRE).
Method Description Advantages Disadvantages
ChIP-seq Chromatin immunoprecipitation of histone-
modifications or TFs coupled with NGS.
Determines genome-wide binding
patterns of protein of interest
Not all enhancers are marked by H3K27ac or
H3K4me1, or tested TFs.
Requires availability of ChIP-grade antibodies.
Cannot determine enhancer activity.
Cannot identify target gene.
ATAC-seq Identification of open chromatin regions by the
transposon Tn5, that cuts the DNA and inserts
sequencing adapters.
Fast.
Requires a low number of cells.
No need for any a priori knowledge.
Other elements are located in open chromatin
regions.
Cannot determine enhancer activity.
Cannot identify target gene.
eRNA detection Detection of the bidirectionally transcribed
eRNA by sequencing the nascent RNA through
techniques such as GRO-seq or CAGE.
Identifies enhancer transcription Not all active enhancers are transcribed.
Chromosome conformation
capture
Detection of topological interactions between
two loci (3C) or genome wide (4C, 5C, Hi-C).
Identifies enhancer-target gene
interactions
Cannot determine enhancer activity.
STARR-seq Identification of functional enhancers by a
massively parallel reporter assay where active






Highly complex plasmid libraries requiring
substantial number of cells for transfection.
Possible false negative results.
CRISPR-Cas9 screenings Endogenous manipulation of enhancers to
force their activation or inactivation.
Identifies functional enhancers.
Can be high-throughput.
Determines the endogenous effect
of enhancer manipulation.
Off-target activity.
Possible false negative results.
500 bp are then selected and used for library preparation
and sequencing (John et al., 2013). FAIRE-seq (Formaldehyde-
Assisted Isolation of Regulatory Elements) is based on the
separation of free and nucleosome-bound DNA. Chromatin is
cross-linked with formaldehyde to covalently bind nucleosomes
to the DNA, and then sonicated and purified by phenol-
chloroform extraction. Nucleosome-bound DNA is sequestered
to the interphase, while accessible DNA can be recovered from
the aqueous phase and sequenced (Giresi and Lieb, 2009).
Finally, the most recently developed method ATAC-seq (Assay
for Transposase Accessible Chromatin with high-throughput
sequencing) exploits the preference of transposons to land in
open chromatin regions. Shortly, the transposon Tn5, loaded
with sequencing adapters, is able to simultaneously cut the DNA
and insert the adapters in a process known as tagmentation.
The open chromatin regions where the transposon preferentially
inserts are then amplified with primers binding to the adapters
and sequenced. Compared to DNase-seq and FAIRE-seq, ATAC-
seq is a simple and fast method that requires less starting
material and does not require gel-purification or crosslinking
reversal steps and is therefore less prone to loss of material
(Buenrostro et al., 2013). However, as mentioned earlier, other
regulatory elements such as insulators or promoters are also
located in accessible chromatin (Boyle et al., 2008). Therefore,
ATAC-seq should be used in combination with other techniques
that are more selective for enhancers. Moreover, these methods
qualitatively identify putative enhancers and do not allow the
quantification of their activity; indeed, also inactive enhancers
can be in open-chromatin regions (Arnold et al., 2013; Catarino
and Stark, 2018). A major advantage of all techniques assessing
chromatin accessibility compared to ChIP-seq is that they screen
for putative regulatory regions in an unbiased way, not requiring
a priori knowledge of enhancer binding factors and not being
restricted to the use of available ChIP-grade antibodies. A recent
study has used ATAC-seq and RNA-seq to determine open
chromatin regions and gene expression at different gestational
weeks, and in different areas of the brain, i.e., the ventricular
zone and the neuronal layers, providing a first glimpse on open
chromatin dynamics during human fetal brain development
(de la Torre-Ubieta et al., 2018).
eRNA
Transcription of enhancer sequences was first reported in the
early 90s in the Locus Control Region (LCR) of the β-globin gene
cluster (Collis et al., 1990; Tuan et al., 1992; Ashe et al., 1997),
where it was found that the expression of the LCR is restricted to
the erythroid lineage. Later, transcription of regulatory elements
into enhancer RNAs (eRNAs) was validated genome-wide with
sequencing, at first, of total neuronal RNA (Kim et al., 2010),
followed by sequencing of nascent RNA (GRO-seq, CAGE)
in different cell types (Wang et al., 2011; Hah et al., 2013;
Kaikkonen et al., 2013; Andersson et al., 2014). Enhancer RNAs
are generally bidirectionally transcribed and not polyadenylated
(Kim et al., 2010) but reports of unidirectional transcription and
polyadenylation of eRNAs exist (Koch et al., 2011). Enhancer
transcription was shown to correlate with the presence of
other enhancer marks such as histone tail post-translational
modifications and p300/CBP and RNApolII binding (Wang et al.,
2011; Hah et al., 2013; Kaikkonen et al., 2013), but whether their
expression is a cause, or a consequence of gene transcription is
still debated (Lam et al., 2014). If eRNA transcription has a direct
functional role and is not just noise due to the recruitment of
RNApolII, the effect can either be mediated by the transcription
process itself or by the transcript produced upon transcription,
which might have direct cis-regulatory activity similar to other
non-coding RNAs such as those involved in X chromosome
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inactivation (Barakat and Gribnau, 2010; Natoli and Andrau,
2012). However, even if eRNA presence correlates with enhancer
activity at some loci, it seems that it is neither required nor
sufficient in all instances (Catarino and Stark, 2018). For example,
a recent study assessing eRNAs in brain only found that around
600 intergenic and intronic enhancers are transcribed in eRNAs,
and this number even further decreased when considering
only those eRNAs replicated in an independent data set or
overlapping with enhancer associated histone modifications (Yao
et al., 2015). The FANTOM project has found a similar small
number of eRNAs in brain, although the majority of those are
not overlapping with those from Yao and colleagues (Andersson
et al., 2014). The number of predicted brain related enhancers
based on other assays by far outnumbers this rather small
set of transcribed enhancers, indicating that methods that just
take eRNA transcription into account may oversimplify the




All methods described until now identify putative enhancers but
understanding which genes they regulate remains a challenge.
Indeed, despite often regulating nearby genes, enhancers can also
be found at long distances from the TSS of their target gene.
Moreover, as abovementioned, it is becoming more and more
clear that chromatin organization plays an important role in
transcription and, as abovementioned, enhancers and promoters
need to be brought in close proximity in order for transcription
to take place. In the past ∼20 years several techniques have
been developed to address this question (reviewed in de Wit
and de Laat, 2012; Davies et al., 2017). The pioneering method,
on which all the later developments are based, is known as
chromosome conformation capture (3C) and relies on the
formaldehyde cross-linking of chromatin within nuclei, followed
by restriction digestion of chromatin and re-ligation by proximity
ligation. The obtained fragments represent the junction of two
chromatin regions that are normally located far away from
each other on the linear genome, but are in close proximity
in 3D space, and these junction products can be quantified by
PCR (Dekker et al., 2002). 3C was developed to study whether
two known regions are interacting with each other and is thus
described as a “one vs. one” method (de Wit and de Laat,
2012). Further advances of 3C-based techniques allowed the
identification of increasing numbers of contacts; for example,
4C, “one vs. all,” allows the identification of all the regions
interacting with a specific site of interest (Simonis et al., 2006;
Zhao et al., 2006), while 5C, “many vs. many,” investigates
all contacts that are happening in a specific locus (Dostie
et al., 2006). Finally, high-throughput contact identification
became possible with Hi-C (Lieberman-Aiden et al., 2009).
Hi-C allows the identification of genome-wide interactions
thanks to the introduction of biotin-labeled nucleotides at
the sites of restriction-digestion. The ends are then ligated,
the chromatin is sheared, and the junctions are enriched by
streptavidin pull-down and sequenced. By the application of an
algorithm on Hi-C data, TADs can be defined. To investigate
all the genome-wide interactions involving a specific protein
of interest, HiChIP was developed, by introducing a chromatin
immunoprecipitation step (Mumbach et al., 2016). This method
has the advantage that it requires less input material and less
sequencing reads.
Despite their capacity to identify enhancer-promoter
interactions and thereby pieces of chromatin with putative
regulatory roles, chromatin conformation techniques have the
disadvantage of not directly measuring functional regulatory
activity. Moreover, in most cases, interactions are determined on
a population level on a high number of cells, which might only
provide a snapshot of dynamic regulatory interactions. Finally,
the spatial resolution at which interactions can be determined is
heavily influenced by the sequencing depth of Hi-C experiments.
Hence, there remains a need for more functional tests to validate
the regulatory activity of the identified interactions. A recent
study has generated Hi-C maps from gestational weeks 15, 16,
and 17 of human brain development, a critical time period for
cortex development (Won et al., 2016), permitting the large-scale
annotation of previously uncharacterized regulatory interactions
relevant to the evolution of human cognition and disease. For
example, the results of this study have linked several non-coding
variants identified in GWAS to genes and pathways involved




As previously highlighted, most of the commonly used
techniques to identify regulatory elements are merely predictive,
and do not directly measure enhancer activity. Although there
is no doubt that techniques such as ChIP-seq, open chromatin
mapping and expression analysis have been of tremendous use to
globally characterize the gene regulatory landscape of the non-
coding genome, it is still clear that there is a need for improved
techniques. In many instances, the identified putative enhancer
sequences fail to perform as enhancers in functional validation
experiments, giving rise to false positive enhancer predictions
(Kwasnieski et al., 2014; Halfon, 2019, for an excellent review).
Moreover, the resolution of commonly used techniques usually
allows the identification of regions in the range of 500–1000 bp
as potentially including an enhancer. But this makes it difficult
to pinpoint those nucleotides that are of real functional relevance
within a given predicted enhancer sequence, and this complicates,
for example, the assignment of functional roles of nucleotide
variants found in the human population. Finally, many of the
currently used techniques take into consideration previously
identified knowledge on associations between epigenetic marks
and putative enhancers. This potentially excludes other regions
of the genome to be functionally assessed as they lack these
associations but might nevertheless be functionally relevant
(Pradeepa et al., 2016). Direct high-throughput functional tests
of enhancer activity, such as massively-parallel reporter assays
(MRPAs) and CRISPR-Cas9 based screens have the potential to
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FIGURE 3 | Methods for functional identification of enhancers. (A) Massively parallel reporter assays (MPRA) to test enhancer activity in an episomal setup. The
putative enhancer sequence is cloned upstream a minimal promoter that drives the expression of a reporter gene and a unique barcode. (B) With STARR-seq the
putative enhancer sequence is cloned downstream the reporter gene and upstream of the polyA signal. When the enhancer sequence is active, it can drive the
expression of the reporter (green) and of itself. In both MPRA and STARR-seq the mRNA is sequenced to identify the active enhancers. (C) Cas9 can be used to
knock out an enhancer at the endogenous genomic locus to assess its effect on the target gene transcription. (D) A catalytically inactive Cas9 (dCas9) can be fused
with activators (A: VP64; TET1; p300) or repressors (R: KRAB; SID4X; DNMT3A; KDM1A). (E) Cas9 screens can be combined with high-throughput screenings by
targeting Cas9 expressing cells with a lentiviral library of gRNA at a low MOI. By doing so, each cell will express a single gRNA and by different selections, such as
drug resistance or reporter gene expression, it is possible to investigate the effect of the ablation of a large number of putative enhancers on gene expression in
parallel.
address these shortcomings (Figure 3), as we will explain in
the next section.
Most traditional functional tests for enhancer activity are
based on reporter assays, in which a putative enhancer sequence
is cloned into a vector with a reporter gene driven by a minimal
promoter that alone is not sufficient to induce reporter gene
expression. The vectors are then transfected into a cell line
or organism of interest, and the reporter gene expression is
determined (Banerji et al., 1981). MPRAs are high throughput
reporter assays where DNA sequences are inserted before the
minimal promoter of a vector with a specific barcode sequence
downstream of the open reading frame, which allows the
simultaneous assessment of 1000s of sequences for enhancer
activity in parallel (Melnikov et al., 2012; Patwardhan et al., 2012;
Arnold et al., 2013; Kheradpour et al., 2013; Whyte et al., 2013;
Dickel et al., 2014; Murtha et al., 2014; Ernst et al., 2016). After cell
transfection, RNA can be purified and sequenced. If the sequence
cloned into the vector is a functional enhancer it drives the
expression of the corresponding barcode. An adapted approach is
Self-Transcribing Active Regulatory Region (STARR) sequencing
(Arnold et al., 2013). STARR-seq takes advantage of the fact
that enhancers act in a position-independent fashion. Indeed,
differently from other MPRAs, STARR-seq does not rely on
barcodes, but the candidate sequences are cloned downstream of
the TSS and, when active, drive their own transcription. With this
assay, millions of sequences can be tested in a single experiment.
In both cases, the activity of the enhancer can be measured by
the relative abundance of the barcode/sequence transcript from
RNA-seq, in comparison to sequencing of the input plasmids.
Similar episomal high-throughput approaches have recently
been developed to also measure promoter responsiveness to
enhancers (Arnold et al., 2017) and autonomous promoter
activity (van Arensbergen et al., 2017).
The major advantage of these tests is that they are unbiased,
since they are not based on any a priori hypothesis about TF
binding or histone modifications. Nevertheless, the size of the
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human genome requires the construction and transfection of
large plasmid libraries, and thus substantial numbers of cells and
deeper sequencing and might therefore lead to a lower resolution.
To overcome this limitation, it is possible to focus STARR-seq
only on putative enhancers, testing only the sequences identified
with ChIP (Barakat et al., 2018), ATAC (Wang X. et al., 2018),
or other techniques (Vanhille et al., 2015; Shen et al., 2016). In
our own application, we have combined ChIP with STARR-seq to
generate genome-wide enhancer activity maps in various types of
human embryonic stem cells (Barakat et al., 2018).
Despite being incredibly useful to test millions of sequences
for enhancer activity in a high-throughput manner, reporter
gene assays may have several limitations. First, enhancer activity
is tested most often on an episomal background, which might
not completely reflect endogenous gene regulation in its native
genomic context (Inoue et al., 2017). Interestingly, recent studies
suggest that the effects of this might be less strong than initially
suggested, as there is a high correlation between episomal
enhancer activity and endogenous gene regulation when assessed
by CRISPR-based deletions (Barakat et al., 2018), or when a
set of enhancers is assessed on both plasmids and integrated
at multiple genomic locations (Maricque et al., 2018). Second,
MPRAs may potentially give false negative results. Indeed, if
a sequence is found inactive in a reporter assay, this does
not exclude that it is active as an enhancer in a different
cell type, in a different moment in time or has another, but
still biologically relevant, role independent on enhancer activity
(Shlyueva et al., 2014).
One way to overcome these possible limitations of transgenic
reporter assays, is to use the recently developed CRISPR-Cas9
system to manipulate NCREs at the endogenous chromatin
context. Cas9 is an RNA-guided DNA endonuclease that is
able to induce double-strand breaks that, in the absence of
a donor template for homology directed repair, are repaired
by the error-prone non-homologous end-joining (NHEJ). The
enhancer sequence can thus be deleted, by targeting Cas9 with
guide-RNAs (gRNAs) flanking the enhancer sequence or be
mutated by the introduction of indels via NHEJ, allowing to
test the effect of the enhancer ablation on gene expression in
the endogenous chromatin environment. Whereas this approach
can be used to study a selected enhancer of interest, as we have
done studying enhancers involved in pluripotency of human
embryonic stem cells (Barakat et al., 2018), it can also be used
in high-throughput screenings with large libraries of gRNAs that
are introduced in cells expressing Cas9. Lentiviral transduction
of gRNAs at a low multiplicity of infection can result in a single
gRNA integration per cell, and in combination with various
means of positive or negative selection, such as drug selection
or assessment of reporter gene expression, this can be used
to investigate in parallel and on a large scale the effect of
multiple putative enhancer ablations on gene expression. To
this end, large populations of cells are transduced, and the
quantitative presence of gRNAs is determined by next generation
sequencing of isolated DNA prior and after a selection. If a
sequence has an important role in gene regulation, the ablation
of that sequence is expected to result in disadvantage for the
cells, and therefore gRNAs targeting relevant functional NCREs
will be depleted over time. By comparing sequencing reads
after and prior to the selection, it is possible to determine
which gRNAs are lost over time, and as the targets of the
gRNAs are known, the relevant NCRE can be identified. In
one of the first applications, DNA regions around the TP53
and ESR1 gene loci were investigated, and it was shown that
this approach was feasible to identify functional enhancers
and, furthermore, using a dense CRISPR-Cas9 gRNA tilling
screen, functional domain within these enhancer sequences
were precisely mapped (Korkmaz et al., 2016). Using a similar
approach, more than 18.000 gRNAs were used to test around
700 kb of sequence flanking genes involved in BRAF inhibitor
resistance in melanoma, finding non-coding regions involved in
gene regulation and chemotherapeutic resistance (Sanjana et al.,
2016). Other studies investigated putative enhancers involved in
oncogene induced senescence (Han et al., 2018), regulation of
the HPRT gene involved in Lesch–Nyhan syndrome (Gasperini
et al., 2017) and regulation of the POU5F1 gene in embryonic
stem cells (Diao et al., 2016, 2017), amongst others (Canver
et al., 2015, 2017; Rajagopal et al., 2016; Sen et al., 2016). Besides
genome-engineering, CRISPR-Cas9 can also be applied to edit
the epigenome, and also this can be coupled to high-throughput
screening. Indeed, by fusing a catalytically dead Cas9 (dCas9),
that lacks endonuclease activity, to various functional domains
it is possible to alter the status of a NCRE forcing its activation or
inactivation, referred to as CRISPRa and CRISPRi, respectively.
Functional additions to dCas9 leading to NCRE activation
include transcription activating domains such as multiple repeats
of the herpes simplex VP16 activation domain (VP64) (Maeder
et al., 2013; Mali et al., 2013), the nuclear factor-κB (NF-κB)
trans-activating subunit activation domain (p65) and human
heat-shock factor 1 (HSF1) (Konermann et al., 2015), the 10–11
translocation methylcytosine dioxygenase 1 (TET1) (Liu X. S.
et al., 2016), and the p300 acetyltransferase (Hilton et al., 2015).
Opposingly, transcription repressive domains that can be used to
silence NCREs include Krüppel-associated box (KRAB) domain
(Gilbert et al., 2013; Thakore et al., 2015), four concatenated
mSin3 domains (SID4X) (Konermann et al., 2013), cytosine-5-
methyltransferase 3A (DNMT3A) (Vojta et al., 2016), Histone
deacetylase 3 (HDAC3) (Kwon et al., 2017), and the lysine-
specific histone demethylase 1A (KDM1A), called dCas9-LSD1
(Kearns et al., 2015). Several of these dCas9 fusion have been
used to activate or repress NCREs, and a number of studies have
used them in high-throughput screening approaches, most of
which focused on NCRE repression (Fulco et al., 2016; Carleton
et al., 2017; Xie et al., 2017; Gasperini et al., 2019) but some
included also NCRE activation (Klann et al., 2017; Simeonov
et al., 2017). It seems only a matter of time till more similar
studies editing NCREs in various cell types using the full CRISPR-
Cas9 toolbox will be published. Obviously, as all experimental
approaches, also CRISPR-Cas9 has its pitfalls and is still far from
perfect. For example, reduced on-target activity and off-target
effects of gRNAs can introduce experimental noise, and it remains
essential that screening results are validated independently. Also,
it remains to be seen whether subtle enhancer effects on gene
expression, that might still be of biological relevance, can be
detected using CRISPR-based screens.
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COMPUTATIONAL APPROACHES
As it has become clear from the discussion above, currently used
enhancer prediction and validation techniques heavily depend on
computational data analysis, most often involving the analysis
of next generation sequencing data. Besides the direct use of
computational analysis for biological data processing, more
and more efforts are undertaken to use computational power
to predict functional NCREs in silico. These methods can be
broadly summarized in approaches that rely on (1) comparative
genomics and evolutionary conservation, (2) clustering of motifs
and epigenome features and machine learning approaches, and
(3) techniques that deal with the processing of data obtained
in functional genomic screens. Here, we mainly focus on the
advantages and disadvantages of some of these methods and
highlight several resources that can be used to obtain information
on genomic enhancer locations. We refer those readers who are
interested in a more detailed discussion on the various options
for machine learning and other prediction tools to a number
of excellent recent reviews (Wang et al., 2013; Suryamohan and
Halfon, 2015; Kleftogiannis et al., 2016; Lim et al., 2018).
Comparative Genomics and Evolution in
Enhancer Prediction
Functional sequences are expected to be more conserved
compared to DNA stretches that are not expected to have
any role, as changing of nucleotide composition is expected to
alter function. This characteristic is exploited by comparative
genomics approaches that aim to identify enhancers by looking
at the most conserved sequences across different species.
This approach was one of the first computational tools to
identify NCREs (Pennacchio et al., 2006; Li et al., 2007).
Nevertheless, different studies showed how some NCREs are
strongly conserved, while others are rapidly changing also in
closely related-species, rendering the solely use of comparative
genomics techniques insufficient. For example, Arnold et al.
(2014) showed by STARR-seq of different Drosophila species how,
in the majority of the cases, enhancer function is conserved
across species, and the highly conserved enhancers are thought to
play an important role during key processes such as embryonic
development, and especially in the developing nervous system
(Pennacchio et al., 2006). However, several other studies suggest
that a portion of enhancers undergo rapid evolution, and that
this might be a crucial driver of human evolution (Degner
et al., 2012; Shibata et al., 2012; Villar et al., 2015; Glinsky and
Barakat, 2019). A subset of active enhancers in human embryonic
stem cells is even enriched in human specific transposable
elements, and those functional regions would be missed if one
were to use only conservation as a key feature for enhancer
selection (Barakat et al., 2018). Therefore, although sometimes
useful, evolutionary conservation alone for the discovery of
NCRE is not recommended as a sole criterion, as it would miss
all the newly evolved enhancers. Another extreme example of
this are so-called ultraconserved elements, stretches of DNA
sequences that are more than 200 bp long and that are 100%
identical in multiple species, such as human, rat and mouse
(Bejerano et al., 2004). Whereas some of these sequences were
shown to play a role as enhancers (Visel et al., 2008; Dickel
et al., 2018), others can be removed from the genome without
an obvious phenotype (Ahituv et al., 2007), and it is speculated
that some of these sequences might contribute to genome stability
(McCole et al., 2018). Enhancers can also be identified by the
presence of specific TFBS, as TF binding is a key characteristic of
these regulatory sequences. Indeed, combining conservation with
TFBS site discovery can further increase the predictive power
of comparative genomic approaches. However, even this does
not guarantee enhancer identification, as during evolution novel
TFBS can appear which execute similar functions as the ones in
the ancestry sequence (Ludwig et al., 2000).
Enhancer Prediction Algorithms
Several types of enhancer predicting algorithms have been
developed for integrating multiple types of data, such as TF
motifs, ChIP-seq, DNase-seq, ATAC-seq, and P300 binding data
sets for enhancer prediction by using clustering and machine
learning approaches. These algorithms include supervised tools
that rely on high-confidence positive and negative training
sets (e.g., known- and non-enhancers) to build models that
can maximize the differentiation between enhancer and non-
enhancer sets, and non-supervised tools that are used to identify
hidden and unknown patterns directly from data. Examples
of supervised algorithms include CSI-ANN (Firpi et al., 2010),
ChromaGenSVM (Fernandez and Miranda-Saavedra, 2012),
RFECS (Rajagopal et al., 2013), EnhancerFinder (Erwin et al.,
2014), DEEP (Kleftogiannis et al., 2015), DELTA (Lu Y. et al.,
2015), PEDLA (Liu F. et al., 2016), REPTILE (He et al., 2017),
eHMM (Zehnder et al., 2019), and DBN (Bu et al., 2017). Other
unsupervised algorithms such as Segway (Hoffman et al., 2012)
and ChromHMM (Ernst and Kellis, 2012) integrate multiple
types of epigenome data to define chromatin segmentations
that can be used to assign functional roles for various parts of
chromatin. One of the main problems of all these prediction
programs is that we still lack a detailed understanding of the
underlying regulatory code in the non-coding genome. Despite
all the advances made over the last decade, we are yet to pinpoint
a feature that can identify enhancers (and their activity) in all cell
types. As most programs rely on previously generated training
sets or on static features such as DNA sequence motifs which by
their own do not necessarily predict enhancers in each instance,
it is more than logical that despite the large amount of efforts
that are undertaken, enhancer prediction programs are far from
perfect. For example, although chromatin segmentation is very
intuitive and access to these segments can be easily obtained from
the UCSC genome browser, it is rather worrying that a recent
study testing more than 2000 sequences classified as enhancers
using these methods did not detect regulatory activity in 74% of
the sequences tested (Kwasnieski et al., 2014). Also the overlap
between individual predictions from various programs is rather
poor (Kleftogiannis et al., 2016). Quite intuitively, programs that
take into account multiple features for enhancer prediction tend
to perform better (Erwin et al., 2014; Dogan et al., 2015; He et al.,
2017). Therefore, it is tempting to speculate that future large-
scale meta-analyses of all currently available enhancer data might
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enable the further fine tuning of enhancer prediction tools in
the near future. Another area where further progress needs to
be achieved is the prediction of enhancer-promoter interactions,
that can be used to assign NCREs to their target genes. Several
tools for this are currently available, such as ELMER 2 and InTAD.
ELMER 2 computes the correlation between the enhancer and
target genes by combining both DNA methylation and gene
expression data derived from the same data set (Silva et al., 2018),
but is limited by the fact that correlations are restricted to the
closest neighboring gene, which does not necessarily present the
real biological relevant target gene (Kvon et al., 2014). InTAD is
a tool to detect genes located upstream and downstream of the
enhancer in the same TAD boundary and it can support different
types of data as input. The TAD information comes from available
Hi-C datasets (Okonechnikov et al., 2019), but the currently
available ones have a low resolutions and, up to date, have
include a limited number of cell types. Therefore, to fully identify
enhancer-gene interactions, it will be important to come up with
novel experimental procedures that will enable us to directly
test the biological relevance of enhancer-promoter predictions.
Finally, a number of programs are developed that aim to predict
the functional relevance and possible pathogenicity of variants
in NCREs. These include, amongst others, RegulomeDB (Boyle
et al., 2012), HaploReg (Ward and Kellis, 2012), CADD (Kircher
et al., 2014), GWAVA (Ritchie et al., 2014), GenoCanyon (Lu Q.
et al., 2015), Genomiser (Smedley et al., 2016), and INFERNO
(Amlie-Wolf et al., 2018). In addition, a number of databases
have been generated, including HEDD (Wang Z. et al., 2018),
DiseaseEnhancer (Zhang et al., 2018), and EnDisease (Zeng et al.,
2019) which have collected NCREs that are related to diseases
based on the current literature. It will be crucial to further expand
and curate these collections of disease relevant enhancers in
the future, and combine them with improved ways of variant
interpretation, to fully exploit the relevance of the non-coding
genome in disease.
Available Enhancer Databases
As the available information on the non-coding genome is
increasing rapidly over the last decade, more and more resources
are available online that can help to localize NCREs and
interpreting their functional roles. In the next part, we summarize
a selection of databases and resources that are currently available
(Table 2) and can be used to find NCREs of relevance for
brain development.
One of the first resources of experimentally tested NCREs
was the VISTA enhancer database (Visel et al., 2007). Based on
comparative genomics, a large selection of putative NCREs from







mouse and human was selected and tested in transgenic mouse
embryo assay, to determine their in vivo enhancer activity, as
determined by LacZ expression. The database provides detailed
information on the genomic localization of the tested sequences,
likely associated genes, and images of transgenic mouse embryos
identifying the localization of enhancer driven LacZ expression.
Based on the 2/25/2019 update, this database contains 542 tested
enhancers active in human forebrain, hindbrain, and midbrain.
In addition, the VISTA tool portal can be used as a comparative
tool and users can submit their own sequences to conduct
comparison against multiple species (Visel et al., 2007), thereby
possibly identifying conserved functional NCREs.
EnhancerAtlas 2.0 is a database that has collected putative
NCREs based on publicly available data obtained from ChIP-
seq for different histone modification, TFs, EP300, and
POLII, CAGE and eRNA expression, interaction studies by
ChIA-PET (a method that combines 3C with chromatin
immunoprecipitation) and chromatin accessibility as determined
by FAIRE and DNase-seq. Each putative enhancer is supported
by at least three independent high-throughput data sets although
the database does not contain any direct functional validations.
It contains more than 4,506,217 putative enhancers from
8,573 datasets of 179 human tissue/cells, which through an
interactive website can be easily accessed. The 49,925 human
fetal brain and 17,103 cerebellum enhancers were predicted
using DNa-seq, CAGE, and H3K4me1, and H3K27ac deposition
(Gao et al., 2016).
The FANTOM5 database, is the latest version of the FANTOM
project, that aims to generate an atlas of mammalian regulatory
elements, transcriptomes, and long-noncoding RNAs. NCREs
are predicted from sequencing data from cap analysis of gene
expression (CAGE) along with RNA-Seq data from multiple
tissue and cell types from different developmental time points
(Andersson et al., 2014). In total, the database contains more than
43,000 putative enhancers, of which 639 are expressed in brain
and 376 were found in neuronal stem cells.
Recently, the PsychENCODE consortium has released data
from a large multi-center effort trying to map NCREs during
brain development (Amiri et al., 2018; Li et al., 2018; Wang D.
et al., 2018). Using analysis of transcriptome, methylation
status, histone modifications and even single cell/nucleus-
level (transcriptome) genomic data, NCREs were discovered
across multiple brain regions over the entire span of human
neurodevelopment and from adult brains, and an integrative data
analysis was performed. These data, generated from age- and
often donor-matched samples, represent the most comprehensive
multi-platform functional genomic analysis of the developing
human brain performed so far. The analysis resulted in 79,056
enhancers identified from adult brains enriched for H3K27ac and
depleted for H3K4me3 (Wang D. et al., 2018). In addition, 96,375
enhancers were shown to interact with protein coding genes
during fetal brain development and during in vitro differentiation
of brain organoids (Amiri et al., 2018). Of the latter, 46,735
enhancers were active only in fetal cortex.
Several super-enhancer databases have been generated such
as dbSUPER (Khan and Zhang, 2016), SEA (Wei et al., 2016),
and SEdb (Jiang et al., 2019) providing annotation, genomic
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FIGURE 4 | Overlap between brain enhancer databases. (A) Venn diagram showing the overlap between brain enhancers (in genome build hg19) from different
databases: VISTA (n = 542) (Visel et al., 2007), dbSUPER (n = 6002) (Khan and Zhang, 2016), FANTOM5 (n = 639) (Andersson et al., 2014), PsychENCODE
(n = 46731; the 46735 enhancers mentioned in the text are in genome build hg38 and the difference of four loci is due to liftover to hg19) (Amiri et al., 2018) and
EnhancerAtlas 2.0 (n = 49925) (Gao et al., 2016). (B) Venn diagram showing the overlap between ChIP-seq peaks for H3K27ac from adult brain, as identified in three
studies: Sun (n = 56503) (Sun et al., 2016), Vermunt (n = 83553) (Vermunt et al., 2014), and Wang (n = 124437) (Wang D. et al., 2018). The intersection between
different sources (in the same order as above) was performed using bedops and bedtools. In both graphs, the minimum overlap of a single nucleotide is required.
coordinates and length of super-enhancers, and their possible
associated genes. Among those, dbSUPER is one of the most
popular databases with 82,234 super-enhancers from multiple
human and mouse cell types. In this database, there are 6,002
and 1,114 super-enhancers detected by H3K27ac enrichment
from seven human and three mouse brain tissues and cell types,
respectively (Khan and Zhang, 2016).
Finally, GeneHancer is a database of human enhancers and
their inferred target genes (Fishilevich et al., 2017). Integrating
enhancer predictions from ENCODE, Ensembl, FANTOM and
VISTA yielded more than 280,000 candidate regions that where
assigned to their target genes based on co-expression correlation,
expression of quantitative trait loci and capture Hi-C.
Although all of these databases can easily be accessed and
are user friendly, it is important to realize when using them
that it is still difficult to judge which of the sources provides
the user with those sequences that are indeed most likely to
be of functional biological relevance. To illustrate this, it is
interesting to compare the overlap between predicted enhancers
from the various resources. When we compare putative
brain enhancers from VISTA, EnhancerAtlas 2.0, FANTOM5,
PsychENCODE and dbSUPER, the overlap between the various
enhancer predictions is rather limited, even when considering
a single nucleotide as the required overlap (Figure 4A). The
same holds true when assessing the overlap between ChIP-
seq peaks for H3K27ac from key adult brain related data
sets (Figure 4B). Intuitively, one would expect that those
NCREs that are found in multiple data sets are more likely
to have a true biological role, although this might be an
oversimplification, as the brain is a very heterogeneous organ
with many different cell types that might differ in NCRE
landscape, and technical limitations might still hinder us from
detecting all relevant NCREs in each cell type. Ideally, future
studies should generate genome-wide functional activity maps of
NCREs for all cell types during brain development. A challenge




DISORDERS AND MALFORMATIONS OF
CORTICAL DEVELOPMENT
As previously discussed, an increasing number of studies
suggests that a high fraction of causative mutations in
neurodevelopmental disorders such as intellectual disability and
autism, belong to pathways of transcriptional regulation and
chromatin remodeling (Gregor et al., 2013; De Rubeis et al., 2014;
Gabriele et al., 2017). Besides mutations in trans-acting factors
such as TFs or chromatin modifiers, also mutations of NCREs
in cis have been proven to be causative of disease in an increasing
number of cases. A classic example is pre-axial polydactyly caused
by alterations of the ZRS, a long-distance enhancer that regulates
Sonic hedgehog (SHH) expression in the embryonic limb (Lettice
et al., 2002; Gurnett et al., 2007). Next to point mutations, also
copy number variation (CNVs) such as duplications (Klopocki
et al., 2008), and insertions (Laurell et al., 2012) in this region
have all been shown to cause polydactyly phenotypes, illustrating
the wide range of alterations that can affect enhancer function
and thereby result in a phenotype. In this section, we discuss
a number of other examples of NCRE alterations, mainly in
relation to disorders affecting the brain (Table 3).
Holoprosencephaly, a neurodevelopmental disorder charac-
terized by craniofacial malformations, can be caused by coding
mutations in the SHH gene. However, a point mutation in the
SHH Brain Enhancer 2 (SBE2) was identified, located 460 kb
upstream of the SHH gene in a patient with an identical
phenotype (Jeong et al., 2008). This mutation was found to
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TABLE 3 | Alterations of non-coding regulatory elements in diseases related to the
central nervous system.
Affected
Disease Mutation gene References
Holoprosencephaly Point mutation SHH Jeong et al., 2008
Aniridia Point mutation PAX6 Bhatia et al., 2013
Polymicrogiria in
the Sylvian fissure
Deletion GPR56 Bae et al., 2014
Parkinson’s disease SNP SNCA Soldner et al., 2016







LMNB1 Giorgio et al., 2015;
Nmezi et al., 2019
Intellectual disability CNV ARX Ishibashi et al., 2015
be disease-causing, as it disrupts the binding site of the TF
SIX3, thereby leading to reduced forebrain SHH expression. In
agreement, also mutations in SIX3 can lead to holoprosencephaly
(Wallis et al., 1999). A disease-causing enhancer mutation is
also found in the congenital eye malformation aniridia, that is
often caused by haploinsufficiency of the TF PAX6, that also
plays crucial roles in neural stem cells. A point mutation in
the PAX6 eye-enhancer was found to disrupt PAX6 binding,
thereby affecting PAX6 expression (Bhatia et al., 2013). In
another example, a 15-base pair deletion in a regulatory element
upstream of an alternative transcript of GPR56 was found in five
individuals from three families (Bae et al., 2014). GPR56, when
mutant in its coding sequence, leads to widespread cobblestone
malformation with cerebellar and white matter abnormalities.
In the patients carrying the 15-bp regulatory element deletion,
polymicrogyria was bilaterally restricted to the Sylvian fissure,
leading to a phenotype of speech delay, intellectual disability
and refractory seizures without further motor involvement. The
authors could show that the deletion disrupts an RFX binding
site, and thereby specifically alters the expression of GPR56 in the
perisylvian and lateral cortex, including the Broca area that is the
primary language area.
Besides influencing disorders presenting early in life, also
disease emerging later in life, such as neurodegenerative disorders
and schizophrenia, are increasingly linked to variants in NCREs.
For example, a risk variant in an enhancer regulating α-synuclein
expression was recently shown to affect gene expression by
altering the binding of the TF EMX2 and NKX6-1 (Soldner
et al., 2016). In addition, tandem duplications of the non-
coding upstream region of VIPR2 have been observed in cases
of schizophrenia and resulted in upregulated VIPR2 expression
(Vacic et al., 2011). Also, CNVs overlapping with NCREs
in other schizophrenia related genes might be implicated in
the disease pathogenesis, influencing the disease vulnerability
(Piluso et al., 2019).
Multiple CNVs have also been associated with periventricular
nodular heterotopia (PNH), a brain malformation in which
nodules of neurons are ectopically retained along the lateral
ventricles (Cellini et al., 2019). Besides changing gene dosage,
CNVs can also change the dosage and position of NCREs,
as well as the higher-order chromatin organization of a locus
(Feuk et al., 2006; Spielmann et al., 2018). Similarly, copy-
number-neutral structural variants, such as inversions and
translocations, can disrupt coding sequences or create fusion
transcripts, but these types of variants can also disrupt or create
new enhancer landscapes and chromatin domains, resulting in
regulatory loss or gain of function. A clinical example of such a
structural variant that changes the 3D architecture of the genome
is the deletion of a TAD boundary at the LMNB1 locus, which
causes an enhancer to regulate a gene that is normally not
regulated by that enhancer (so-called enhancer adoption). In this
case, the enhancer adoption leads to adult-onset demyelinating
leukodystrophy (ADLD), which is a progressive neurologic
disorder affecting the myelination of the central nervous system
(Giorgio et al., 2015). More recently, deletions upstream of
LMNB1, varying in size from 250 to 670 kb, occurring in
repetitive elements, have revealed increased LMNB1 expression
and an atypical ADLD phenotype (Nmezi et al., 2019). Other
rare inherited structural variants in cis-regulatory elements might
influence the risk for children of developing autism spectrum
disorders (ASDs), depending on the parental origin of the
structural variant (Brandler et al., 2018). Another study on
autism using whole genome sequencing (WGS) on more than
2000 individuals found that probands carry more gene-disruptive
CNVs and SNVs resulting in severe missense mutations and
mapping to predicted fetal brain promoters and embryonic
stem cell enhancers (Turner et al., 2017). In addition, CNVs
covering the regulatory elements of the ARX gene might cause an
intellectual disability phenotype (Ishibashi et al., 2015), and rare
non-coding CNVs near previously known epilepsy genes were
enriched in a cohort of 198 individuals affected with epilepsy
compared to controls (Monlong et al., 2018). Similar findings
are reported for multiple system atrophy (Hama et al., 2017)
and non-coding variants might influence expression of GLUT1
causing epilepsy (Liu Y.C. et al., 2016).
Two large-scale analyses focused on NCREs and their role
in neurodevelopmental disorders have recently been performed.
Using a targeted sequencing approach, Short and colleagues
studied de novo occurring genomic variants in three classes of
putative regulatory elements in 7,930 individuals suffering from
developmental disorders from the Deciphering Developmental
Disorders (DDDs) study and their parents. The three classes
of regulatory elements that they assessed consisted of 4,307
highly evolutionarily conserved non-coding elements (Siepel
et al., 2005), 595 experimentally validated enhancers (Visel
et al., 2007), and 1,237 putative heart enhancers (May et al.,
2011), together covering 4.2 Mb of genomic sequence. In the
6,239 individuals in which exome sequencing did not find a
disease cause, they found that conserved non-coding elements
were nominally significantly enriched for de novo variants (422
observed, 388 expected, P = 0.04), whereas in experimentally
validated enhancers (153 observed, 156 expected, P = 0.605),
heart enhancers (86 observed, 86 expected, P = 0.514), and
intronic controls (901 observed, 919 expected, P = 0.728)
de novo variants were not enriched. When focusing only on
conserved non-coding elements that had evidence of activity
in brain, they observed an even stronger enrichment. Based
on their analysis, the authors estimate that only around 1–3%
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of exome-negative individuals will be explained by de novo
variants in fetal brain-active regulatory elements. However, as
in this study only de novo variants were assessed, and only a
limited set of regulatory elements was used which were already
defined in 2010, this is likely an underestimation of the possible
impact of the non-coding genome for neurodevelopmental
disorders. Doan and colleagues performed a similar targeted
sequencing approach assessing so-called human accelerated
regions (HARs) (Doan et al., 2016). HARs are conserved
regions with elevated divergence in humans and this might
reflect potential roles in the evolution of human-specific traits.
This study provides evidence that HARs can function as
regulatory elements for dosage-sensitive genes expressed in the
central nervous system. Using data from a large cohort study
investigating 2100 sibling cases of ASD, they found that de
novo CNV’s affecting HARs, or HAR-containing genes, could
be implicated in up to 1.9% of ASD cases in simplex families.
They then analyzed consanguineous ASD cases using WGS
from 30 affected and 5 unaffected individuals and designed
a custom capture array to sequence HARs in another 188
affected and 172 unaffected individuals. Individuals with ASD
exhibited an excess of rare (AF < 0.5%) bi-allelic HAR alleles
(43% excess compared to unaffected, P = 0.008), and this
enrichment further increased when only taking HARs in to
consideration that were likely active as regulatory elements in
brain. Using MPRA, 343 bi-allelic HAR variants were functionally
tested, and 29% of these were shown to alter the regulatory
activity of the reference sequence. Therefore, the enrichment
of regulation-altering variants in HARs with predicted activity
suggests that many may contribute to the pathogenesis and
diversity of ASD. They further functionally validated their
findings in three examples of bi-allelic variants in HARs identified
in ASD families, regulating the genes CUX1, PTBP2 and GPC4,
further providing evidence that the investigation of NCREs
such as HARs is promising to solve currently genetically
unexplained disease cases.
What appears from the examples given above, is that a
wide range of NCRE alterations can result in effects on gene
transcription, leading to a disease phenotype. This can vary from
point mutations affecting the binding of crucial TFs, deletions
or duplications of NCRE sequences, shuﬄing of the genomic
location of NCREs affecting their function (e.g., enhancer
adoption) or alterations in the global chromatin landscape
disrupting borders of TADs, just to mention a few. Given
the complexity that can exist in these disease mechanisms,
and the current shortcomings in understanding the complete
functionality of the non-coding genome, it seems likely that in the
next decade many more examples of NCRE alteration in genetic
disease will be identified.
THE FUTURE AHEAD
As we have discussed in this Review, our understanding of
gene regulation has deepened over the last decade. NCREs
have been identified as crucial modifiers of gene expression,
and more and more examples of their involvement in human
genetic disorders, when mutant, are being reported. In routine
clinical practice genetic analysis has mainly focused on the
∼2% of the genome that directly encodes for proteins. Most
of the non-coding part has been instead neglected, and only
recently we could witness a shift of attention toward these
sequences. It seems intuitive that, if human evolution resulted
in a large and subsequently maintained expansion of the non-
coding genome, this should have a functional role, and alterations
of these sequences should influence their function and lead to
genetic disorders. Given the fact that MCDs are often genetically
unexplained despite the routine use of WES, it would be
surprising if, in the near future, no genetic alterations of non-
coding sequences will be identified in those currently unexplained
patients. In order to achieve this, it is crucial to develop novel
diagnostic approaches focusing on non-coding regions. Will
WGS be useful to find disease causes in those unexplained
MCD patients in a clinical setting? Theoretically yes as it
will enable the identification of all detectable variants genome-
wide, but our current understanding of genomic variation
outside exons severely hampers its routine implementation.
As a matter of fact, most studies that have used WGS in a
clinical setting, have limited their analysis to those nucleotides
covering exons, deep intronic variants not covered in WES and
copy number and structural variants (Stavropoulos et al., 2016;
Lionel et al., 2018; Clark et al., 2019; Scocchia et al., 2019).
Therefore, it remains crucial to gain more detailed information
on the functional relevance of NCREs and their variants from
a basic science point of view. Although the characterization
of epigenomic marks such as histone modifications has shown
to be useful to identify functional NCREs, it is clear from
the discussion above that there are still some pitfalls, as we
still lack the perfect mark to identify relevant and active
NCREs. One particular concern is that many studies assume that
investigating a single histone modification, such as H3K27ac,
gives sufficient evidence to call a region a functional NCRE,
but this is certainly an oversimplification. As we have argued
above, predicted NCREs should remain classified as putative
NCREs till they are functionally validated, or at least predicted
in multiple studies ideally using different techniques to obtain a
higher level of confidence in their function. In current studies,
functional validations of putative NCREs is often performed
only for a selected number of regions of interest and results
of these few validations are extrapolated to the complete data
set generated. Even though this is understandable from a
pragmatic experimental point of view, it might be one of the
reasons for the broad level of variation between predicted
enhancers from different sources. Hence, it is crucial to further
develop high-throughput approaches for functional validation
studies so that more sequences and their variants can be
directly functionally tested, leading to a higher confidence in
the data resources. The future application of direct functional
assays, such as MPRAs and CRISPR-Cas9 based screens, is
expected to further add on to our current understanding, even
though also these methods are far from perfect yet. Besides
these emerging experimental techniques, it is also crucial to
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develop novel computational tools that outperform currently
available programs for NCRE prediction and disease annotation.
Similarly, it is also important to further improve the linking
between NCREs and their target genes, going beyond the current
resolution of chromatin conformation capture or correlation
between activity of putative enhancers and expression of
possibly linked genes. Until we will have all these ideal tools
widely available, in our opinion the best practice to study
the role of the non-coding genome in genetic disorders such
as MCDs is to study genetic variation outside exomes in
well-defined, exome negative patients and preferably combine
this with a direct readout of gene expression in a disease
relevant tissue. For the functional annotation of the non-
coding variants found in patients, it is essential to use as
many sources of information as possible, enabling the highest
level of confidence in defining a certain region a regulatory
sequence. And last but certainly not least, a detailed clinical
phenotyping of patients prior to any genetic investigation
remains crucial as it allows the comparison of patients with
similar non-coding variants and shared phenotypes. Even in
an era where it is cheap to sequence a whole genome, reverse
phenotyping of patients remains essential to learn more about
the consequences of the genetic variants and to further mature
our understanding of the non-coding genome beyond the
borders of the exome.
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